Serum syndecan-4 as a possible biomarker in patients with acute pneumonia

Journal of Infectious Diseases

Volumn 212, Issue 9, 2015, Pages 1500-1508

  Nikaido, Takefumi ^a   Tanino, Yoshinori ^a   Wang, Xintao ^a   Sato, Suguru ^a   Misa, Kenichi ^a   Fukuhara, Naoko ^a   Sato, Yuki ^a   Fukuhara, Atsuro ^a   Uematsu, Manabu ^a   Suzuki, Yasuhito ^a   Kojima, Tetsuhito ^b   Tanino, Mishie ^c   Endo, Yuichi ^a   Tsuchiya, Kohsuke ^d   Kawamura, Ikuo ^d   Frevert, Charles W ^e,f   Munakata, Mitsuru ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

acute bacterial pneumonia; biomarker; S. pneumoniae; survival; syndecan 4

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CXCL1 CHEMOKINE; CXCL3 CHEMOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; SYNDECAN 4; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CYTOKINE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; BACTERIAL PNEUMONIA; BACTERIUM IDENTIFICATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENE EXPRESSION REGULATION; HOSPITAL ADMISSION; HUMAN; LONG TERM CARE; LUNG LAVAGE; MALE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SHORT COURSE THERAPY; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; UPREGULATION; WILD TYPE; ACUTE DISEASE; ANIMAL; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MIDDLE AGED; NEUTROPHIL; PNEUMONIA, BACTERIAL;

ACUTE DISEASE; AGED; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BIOMARKERS; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; FEMALE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; NEUTROPHILS; PNEUMONIA, BACTERIAL; STREPTOCOCCUS PNEUMONIAE; SYNDECAN-4;

EID: 84938221203     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv234     Document Type: Article

References (46)

1. World Health Organization. The top 10 causes of death in the world, 2000 and 2011. http://www.who.int/mediacentre/factsheets/fs310/en/index.html. Accessed 9 January 2014
2. Pitter JF, Mackersie RC, Martin TR, Matthay MA. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am J Respir Crit Care Med 1997; 155: 1187-205
3. Segel GB, Halterman MW, Lichtman MA. The paradox of the neutrophil s role in tissue injury. J Leukoc Biol 2011; 89: 359-72
4. Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest 2001; 108: 169-73
5. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans finetune mammalian physiology. Nature 2007; 446: 1030-7
6. Gill S, Wight TN, Frevert CW. Proteoglycans: key regulators of pulmonary inflammation and the innate immune response to the lung infection. Anat Rec (Hoboken) 2010; 293: 968-81
7. Parish CR. The role of heparan sulphate in inflammation. Nat Rev Immunol 2006; 6: 633-43
8. Celie JW, Beelen RH, van den Born J. Heparan sulfate proteoglycans in extravasation: assisting leukocyte guidance. Front Biosci (Landmark Ed) 2009; 14: 4932-49
9. Bartlett AH, Hayashida K, Park PW. Molecular and cellular mechanisms of syndecans in tissue injury and inflammation. Mol Cells 2007; 24: 153-6
10. Alexopoulou AN, Multhaupt HA, Couchman JR. Syndecans in wound healing, inflammation and vascular biology. Int J Biochem Cell Biol 2007; 39: 505-28
11. Götte M. Syndecans in inflammation. FASEB J 2003; 17: 575-91
12. Saphire AC, Bobardt MD, Zhang Z, David G, Gallay PA. Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages. J Virol 2001; 75: 9187-200
13. Bernfield M, Kokenyesi R, Kato M, et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 1992; 8: 365-93
14. Okuyama E, Suzuki A, Murata M, et al. Molecular mechanisms of syndecan-4 upregulation by TNF - A in the endothelium-like EAhy926 cells. J Biochem 2013; 154: 41-50
15. Li Q, Park PW, Wilson CL, Parks WC. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002; 111: 635-46
16. Brule S, Charnaux N, Sutton A, et al. The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology 2006; 16: 488-501
17. Pruessmeyer J, Martin C, Hess FM, et al. A disintegrin and metalloproteinase 17 (ADAM17) mediates inflammation-induced shedding of syndecan-1 and -4 by lung epithelial cells. J Biol Chem 2010; 285: 555-64
18. Ramnath R, Foster RR, Qiu Y, et al. Matrix metalloproteinase 9-mediated shedding of syndecan-4 in response to tumor necrosis factor a: a contributor to endothelial cell glycocalyx dysfunction. FASEB J 2014; 28: 4686-99
19. Frevert CW, Kinsella MG, Vathanaprida C, et al. Binding of interleukin-8 to heparan sulfate and chondroitin sulfate in lung tissue. Am J Respir Cell Mol Biol 2003; 28: 464-72
20. Muramatsu T, Muramatsu H, Kojima T. Identification of proteoglycanbinding proteins. Methods Enzymol 2006; 416: 263-78
21. Tanino Y, Chang MY, Wang X, et al. Syndecan-4 regulates early neutrophil migration and pulmonary inflammation in response to lipopolysaccharide. Am J Respir Cell Mol Biol 2012; 47: 196-202
22. Inokoshi Y, Tanino Y, Wang X, et al. Clinical significance of serum hyaluronan in chronic fibrotic interstitial pneumonia. Respirology 2013; 18: 1236-43
23. Kohno S, Seki M, Watanabe A. Evaluation of an assessment system for the JRS 2005: A-DROP for the management of CAP in adults. Intern Med 2011; 50: 1183-91
24. Kasamatsu Y, Yamaguchi T, Kawaguchi T, et al. Usefulness of a semiquantitative procalcitonin test and the A-DROP Japanese prognostic scale for predicting mortality among adults hospitalized with community-acquired pneumonia. Respiration 2012; 17: 330-6
25. Kono S, Seki M, Takehara K, et al. Prediction of requirement formechanical ventilation in community-acquired pneumonia with acute respiratory failure; a multicenter prospective study. Respiration 2013; 85: 27-35
26. Ishiguro K, Kadomatsu K, Kojima T, et al. Syndecan-4 deficiency impairs focal adhesion formation only under restricted condition. J Biol Chem 2000; 275: 5249-52
27. Wang X, Ohtsuka Y, Kimura K, et al. Mannose-binding lectin gene polymorphisms and the development of coal workers pneumoconiosis in Japan. Am J Ind Med 2008; 51: 548-53
28. Endo Y, Takahashi M, Iwaki D, et al. Mice deficient in ficolin, a lectin complement pathway recognition molecule, are susceptible to Streptococcus pneumoniae infection. J Immunol 2012; 189: 5860-6
29. Tanino Y, Makita H, Miyamoto K, et al. Role of macrophage migration inhibitory factor in bleomycin-induced lung injury and fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2002; 283: L156-62
30. Ishiguro K, Kadomatsu K, Kojima T, et al. Syndecan-4 deficiency leads to high mortality of lipopolysaccharide-injected mice. J Biol Chem 2001; 276: 47483-8
31. Smith MF Jr, Novotny J, Carl VS, Comeau LD. Helicobacter pylori and Toll-like receptor agonists induce syndecan-4 expression in an NF-?-dependent manner. Glycobiology 2006; 16: 221-9
32. Tan X, Khalil N, Tesarik C, et al. Th1cytokine-induced syndecan-4 shedding by airway smooth muscle cells independent on mitogen-activated protein kinases. Am J Physiol Lung Cell Mol Physiol 2012; 302: L700-10
33. Kaneider NC, Egger P, Dunzendorfer S, Wiedermann CJ. Syndecan-4 as antithrombin receptor of human neutrophils. Biochem Biophys Res Commun 2001; 287: 42-6
34. Xu J, Park PW, Kheradmand F, Corry DB. Endogenous attenuation of allergic lung inflammation by syndecan-1. J Immunol 2005; 174: 5758-65
35. Tanino Y, Coombe DR, Gill SE, et al. Kinetics of chemokine-glycosaminoglycan interaction control neutrophil migration into the airspaces of the lung. J Immunol 2010; 184: 2677-85
36. Ishiguro K, Kadomatsu K, Kojima T, et al. Syndecan-4 deficiency increased susceptibility to ?-carrageenan-induced renal damage. Lab Invest 2001; 81: 509-16
37. Cevikbas F, Schaefer L, Uhlig P, et al. Unilateral nephrectomy leads to up-regulation of syndecan-2-and TGF-beta-mediated glomerulosclerosis in syndecan-4 deficient male mice. Matrix Biol 2008; 27: 42-52
38. Kon S, Ikesue M, Kimura C, et al. Syndecan-4 protects hepatic injury by masking functional domains of osteopontin. J Exp Med 2008; 205: 25-33
39. Matsui Y, Ikesue M, Danzaki K, et al. Syndecan-4 prevents cardiac rupture and dysfunction after myocardial infarction. Circ Res 2011; 108: 1328-39
40. Echtermeyer F, Streit M, Wilcox-Adelman S, et al. Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J Clin Invest 2001; 107: R9-17
41. Tonnaer EL, Hafmans TG, Van Kuppevelt TH, Sanders EA, Verweij PE, Curfs JH. Involvement of glycosaminoglycans in the attachment of pneumococci to nasopharyngeal epithelial cells. Microbes Infect 2006; 8: 316-22
42. Hagiwara S, Iwasaka H, Hidaka S, Hishiyama S, Noguchi T. Danaparoid sodium inhibits systemic inflammation and prevents endotoxininduced acute lung injury in rat. Crit Care 2008; 12: R43
43. Iba T, Miyasho T. Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function in endotoxemic rats. Crit Care 2008; 12: R86
44. Severin IC, Soares A, Hantson J, et al. Glycosaminoglycan analog as a novel anti-inflammatory strategy. Front Immunol 2012; 3: 293
45. Chuang KH, Peng YC, Chien HY, Lu ML, Du HI, Wu YL. Attenuation of LPS-induced lung inflammation by glucosamine in rat. Am J Respir Cell Mol Biol 2013; 49: 1110-9
46. Xie J, Wang J, Li R, et al. Syndecan-4 over-expression preserves cardiac function in a rat model of myocardial infarction. J Mol Cell Cardiol 2012; 53: 250-8